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Abstract
Enrichment analysis has been widely applied in the genome-wide association studies (GWAS), 
where gene sets corresponding to biological pathways are examined for significant associations 
with a phenotype to help increase statistical power and improve biological interpretation. In this 
work, we expand the scope of enrichment analysis into brain imaging genetics, an emerging field 
that studies how genetic variation influences brain structure and function measured by 
neuroimaging quantitative traits (QT). Given the high dimensionality of both imaging and genetic 
data, we propose to study Imaging Genetic Enrichment Analysis (IGEA), a new enrichment 
analysis paradigm that jointly considers meaningful gene sets (GS) and brain circuits (BC) and 
examines whether any given GS-BC pair is enriched in a list of gene-QT findings. Using gene 
expression data from Allen Human Brain Atlas and imaging genetics data from Alzheimer’s 
Disease Neuroimaging Initiative as test beds, we present an IGEA framework and conduct a 
proof-of-concept study. This empirical study identifies 12 significant high level two dimensional 
imaging genetics modules. Many of these modules are relevant to a variety of neurobiological 
pathways or neurodegenerative diseases, showing the promise of the proposal framework for 
providing insight into the mechanism of complex diseases.
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1 Introduction
Brain imaging genetics is an emerging field that studies how genetic variation influences 
brain structure and function. Genome-wide association studies (GWAS) have been 
performed to identify genetic markers such as single nucleotide polymorphisms (SNPs) that 
are associated with brain imaging quantitative traits (QTs) [15, 16]. Using biological 
pathways and networks as prior knowledge, enrichment analysis has also been performed to 
discover pathways or network modules enriched by GWAS findings to enhance statistical 
power and help biological interpretation [5]. For example, numerous studies on complex 
diseases have demonstrated that genes functioning in the same pathway can influence 
imaging QTs collectively even when constituent SNPs do not show significant association 
individually [13]. Enrichment analysis can also help identify relevant pathways and improve 
mechanistic understanding of underlying neurobiology [6,10,11,14].
In the genetic domain, enrichment analysis has been widely studied in gene expression data 
analysis and has recently been modified to analyze GWAS data. GWAS-based enrichment 
analysis first maps SNP-level scores to gene-level scores, and then test whether a pre-
defined gene set S (e.g., a pathway) is enriched in a set of significant genes L (e.g., GWAS 
findings). Two strategies are often used to compute enrichment significance: threshold-
based [3, 4, 8, 19] and rank-based [17]. Threshold-based approaches aim to solve an 
independence test problem (e.g., chi-square test, hypergeometric test, or binomial z-test) by 
treating genes as significant if their scores exceed a threshold. Rank-based methods take into 
account the score of each gene to determine if the members of S are randomly distributed 
throughout L.
In brain imaging genetics, the above enrichment analysis methods are applicable only to 
genetic findings associated with each single imaging QT. Our ultimate goal is to discover 
high level associations between meaningful gene sets (GS) and brain circuits (BC), which 
typically include multiple genes and multiple QTs. To achieve this goal, we propose to study 
Imaging Genetic Enrichment Analysis (IGEA), a new enrichment analysis paradigm that 
jointly considers sets of interest (i.e., GS and BC) in both genetic and imaging domains and 
examines whether any given GS-BC pair is enriched in a list of gene-QT findings.
Using whole brain whole genome gene expression data from Allen Human Brain Atlas 
(AHBA) and imaging genetics data from Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) as test beds, we present a novel IGEA framework and conduct a proof-of-concept 
study to explore high level imaging genetic associations based on brain-wide genome-wide 
association study (BWGWAS) results. For consistency purpose, in this paper, we use GS to 
indicate a set of genes and BC to indicate a set of regions of interest (ROIs) in the brain. The 
proposed framework consists of the following steps (see also Figure 1): (1) use AHBA to 
identify meaningful GS-BC modules, (2) conduct BWGWAS on ADNI amyloid imaging 
genetics data to identify SNP-QT and gene-QT associations, (3) perform IGEA to identify 
GS-BC modules significantly enriched by gene-QT associations using threshold-based 
strategy, and (4) visualize and interpret the identified GS-BC modules.
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2 Methods and Materials
2.1 Brain Wide Genome Wide Association Study (BWGWAS)
The imaging and genotyping data used for BWGWAS were obtained from the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). One goal of ADNI 
has been to test whether serial magnetic resonance imaging (MRI), positron emission 
tomography (PET), other biological markers, and clinical and neuropsychological 
assessment can be combined to measure the progression of mild cognitive impairment 
(MCI) and early AD. For up-to-date information, see www.adni-info.org. Preprocessed 
[18F]Florbetapir PET scans (i.e., amyloid imaging data) were downloaded from 
adni.loni.usc.edu, then aligned to each participant’s same visit scan and normalized to the 
Montreal Neurological Institute (MNI) space as 2 × 2 × 2 mm voxels. ROI level amyloid 
measurements were further extracted based on the MarsBaR AAL atlas. Genotype data of 
both ADNI-1 and ADNI-GO/2 phases were also downloaded, and then quality controlled, 
imputed and combined as decribed in [9]. A total of 980 non-Hispanic Caucasian 
participants with both complete amyloid measurements and genome-wide data were studied. 
Associations between 105 (out of a total 116) baseline amyloid measures and 5,574,300 
SNPs were examined by performing SNP-based GWAS using PLINK [12] with sex, age and 
education as covariates. To facilitate the subsequent enrichment analysis, a gene-level p-
value was determined as the smallest p-value of all SNPs located in ±50K bp of the gene.
2.2 Constructing GS-BC Modules using AHBA
There are many types of prior knowledge that can be used to define meaningful GS and BC 
entities. In the genomic domain, the prior knowledge could be based on Gene Ontology or 
functional annotation databases; in the imaging domain, the prior knowledge could be 
neuroanatomic ontology or brain databases. In this work, to demonstrate the proposed IGEA 
framework, we use gene expression data from the Allen Human Brain Atlas (AHBA, Allen 
Institute for Brain Science, Seattle, WA; available from http://www.brain-map.org/) to 
extract GS and BC modules such that genes within a GS share similar expression profiles 
and so do ROIs within a BC. We hypothesize that, given these similar co-expression 
patterns across genes and ROIs, each GS-BC pair forms an interesting high level imaging 
genetic entity that may be related to certain biological function and can serve as a valuable 
candidate for two-dimensional IGEA.
The AHBA includes genome-wide microarray-based expression covering the entire brain 
through systematic sampling of regional tissue. Expression profiles for eight health human 
brains have been released, including two full brains and six right hemispheres. One goal of 
AHBA is to combine genomics with the neuroanatomy to better understand the connections 
between genes and brain functioning. As an early report indicated that individuals share as 
much as 95% gene expression profile [21], in this study, we only included one full brain 
(H0351.2001) to construct GS-BC modules. First all the brain samples (~ 900) were mapped 
to MarsBaR AAL atlas, which included 116 brain ROIs. Due to many-to-one mapping from 
brain samples to AAL ROIs, there are > 1 samples for each ROI. Following [20], samples 
located in the same ROI were merged using the mean statistics. Probes were then merged to 
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genes using the same strategy. Finally the preprocessed gene-ROI profiles were normalized 
for each ROI. As a result, the expression matrix contained 16,097 genes over 105 ROIs.
We performed a 2D cluster analysis on the gene-ROI expression matrix to identify 
interesting GS-BC modules. First, we calculated the distance matrices for both genes and 
ROIs, respectively. In other words, we computed the dissimilarity between each pair of 
genes, and the dissimilarity between each pair of ROIs, using Equation (1).
(1)
Two dendrograms were constructed by applying hierarchical clustering to two distance 
matrices separately, using the UPGMA (Unweighted Pair Group Method with Arithmetic 
Mean) algorithm. As most enrichment analyses placed constraints on genetic pathways of 
sizes from 10 to 400 [13], we cut the dendrogram at half of its height to build genetic 
clusters (i.e., GSs) whose sizes are mostly within the above range. For the imaging domain, 
we also employed the same parameter to construct ROI clusters (i.e., BCs).
We tested the statistical significance of each GS-BC pair based on a null hypothesis that the 
expression level of a gene is independent from the expression level of other genes across 
relevant brain ROIs in the same GS-BC module, assuming that the average Pearson’s 
correlation coefficients (PCCs) of gene expression levels for genes in the GS-BC module are 
higher than the ones from random GS-BC modules. Thus, for each GS-BC module, we 
constructed another GS-BC module with the same number of randomly selected genes and 
ROIs, and calculated its average PCC (avgPCC), This procedure was repeated N = 1000 
times and the empirical p-value of original GS-BC module was calculated using the 
following equation, where I is an indicator function [7].
(2)
2.3 Imaging Genetic Enrichment Analysis (IGEA)
Pathway enrichment analysis has been extensively employed to genomic domain to analyze 
the genetic findings associated with a specific imaging QT. In this study, our goal is to 
identify high level associations between gene sets and brain circuits, which typically include 
multiple genes and multiple QTs.
In this study, we propose the threshold-based IGEA by extending the existing threshold-
based enrichment analysis. SNP level findings have been mapped to gene level findings in 
Section 2.1. The GWAS findings are a list L of N = NG × NB gene-QT associations, where 
we have a set Gd of NG = |Gd| genes and a set Bd of NB = |Bd| QTs in our analysis. From 
Section 2.2, significant GS-BC modules, where relevant genes share similar expression 
profiles across relevant ROIs, have been constructed. Given an interesting GS-BC module 
with gene set Gk and QT set Bk, IGEA aims to determine whether the target GS-BC module 
T = {(g, b)|g ∈ Gd ∩ Gk, b ∈ Bd ∩ Bk} is enriched in L.
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Now we describe our threshold-based IGEA method. We have N gene-QT pairs from 
GWAS. Out of these, n = |A| pairs (the set A) are significant ones with GWAS p-value 
passed a certain threshold. We also have m = |P| (the set P) gene-QT pairs from a given GS-
BC module, and k significant pairs are from P. Using Fisher’s exact test for independence, 
the enrichment p-value for the given GS-BC module is calculated as:
(3)
2.4 Evaluation of the Identified GS-BC Modules
For evaluation purpose, we tested the statistical significance of the IGEA results. We 
hypothesize that the gene-QT associations from BWGWAS of the original data should be 
overrepresented in certain GS-BC modules, and the BWGWAS results on permuted data 
should not be enriched in a similar number of GS-BC modules. We performed IGEA 
analyses on 50 permuted BWGWAS data sets, and estimated the distribution of the number 
of significant GS-BC modules. The distribution appeared to be normal. Using this normal 
distribution, we estimated an empirical p-value for the number of significant GS-BC 
modules discovered from the original data.
To determine the functional relevance of the enriched GS-BC modules, we also tested 
whether genes from each module are overrepresented for specific neurobiological functions, 
signaling pathways or complex neurodegenerative diseases. We performed pathway 
enrichment tests using gene ontology (GO) biological process terms, KEGG pathways and 
OMIM (Online Mendelian Inheritance in Man) database.
3 Results and Discussions
3.1 Significant GS-BC Modules from AHBA
By performing hierarchical clustering on both genetic and imaging domains, 275 out of 357 
genetic clusters (only those with size ranging from 10 to 400) and 8 imaging clusters (with 
size ranging from 4 to 23, no clusters are excluded) were identified. 2200 GS-BC modules 
were generated by combining each pair of genetic and ROI clusters. After performing 1000 
permutation tests, 610 modules were kept with a p-value ≤ 0.05. We did not use extremely 
stringent statistical thresholds for the selection, to avoid the exclusion of potentially 
interesting candidates. For the BWGWAS results, we obtained 21, 028 × 105 = 2, 207, 940 
gene-QT associations after mapping SNP-based p-values to genes. Out of these, 1679 gene-
QT associations passed the BWGWAS p-value of 1.0E-5.
All 610 constructed GS-BC modules were tested for whether they could be enriched by 
BWGWAS results using IGEA, and 12 of them turned out to be significant after Bonferroni 
correction (see Table 1). We also tested the significance of the number of identified GS-BC 
modules. Compared to permuted results, the analysis on the original data yielded a 
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significantly larger number of enriched GS-BC modules with empirical p-value = 2.6E-2, 
indicating that imaging genetic associations existed in these enriched GS-BC modules.
Across all 12 identified modules, there are 5 and 7 unique GS and BC entities respectively. 
Table 2 lists the 5 unique GSs with gene symbols. Figure 2 shows the 7 unique BCs with 
corresponding ROI names, and Figure 3 maps four of those onto the brain. For example, 
BC01 involves structures responsible for motivated behaviors (e.g., caudate, pallidum, 
putamen) and sensory information processing (e.g., thalamus). BC02 involves various 
frontal regions responsible for executive functions. BC06 includes structures that are major 
spots for amyloid accumulation in AD (e.g., cingulum, precuneus). Details of all 12 modules 
are listed in Table 1. We can find that some modules share common gene sets with different 
brain circuits, and some share the same brain circuits with different gene sets. This 
illustrates the complex associations among multiple genes and multiple brain ROIs.
3.2 Pathway Analysis of Identified GS-BC Modules
To explore and analyze functional relevance of our identified GS-BC modules, we 
performed pathway analysis from three aspects including biological processes, functional 
pathways and diseases using Gene Ontology, KEGG pathways and OMIM diseases 
databases, respectively.
Most identified GSs have a significant functional enrichment, and several can be related to 
the neurodegenerative disease and its development. For instance, calcium signaling pathway 
(from Module #01 and #02) playing key role in short- and long-term synaptic plasticity, has 
shown abnormality in many neurodegenerative disorders including AD, Parkinson’s disease, 
amyotrophic lateral sclerosis, Huntington’s disease, spinocerebellar ataxias and so on [1]. 
There are also several enriched pathways related to oxidative stress, which is a critical factor 
for a range of neurodegenerative disorders. For example, DNA polymerase (from Module 
#04-08) deficiency can lead to neurodegeneration and exacerbates AD phenotypes by 
reducing repair of oxidative DNA damage [18]; glycolysis and gluconeogenesis (from 
Module #04-08) are associated with hypoxia, ischemia, and AD [2]; others like adherens 
junction (from Module #12) and focal adhesion (from Module #03) have also been shown 
disorder-related by indirectly affecting oxidative stress. For the enriched disease results, we 
also find some neurodegeneration-related (like anomalies from Module #01 and #02, 
neuropathy from module #04-08), while a large part of them are cancer-related (like prostate 
cancer from Module #09, #10 and #11). A large body of studies have focused on 
investigating the relationship between cancer and neurodegeneration, with abnormal cell 
growth and cell loss in common. For the GO Biological Process enrichment, various 
Biological Process terms are enriched and can be grouped to 5 categories including cellular 
process, cell cycle, metabolic process, neurological system process and response to stimulus. 
Most of these terms have direct or indirect relationships with neurodegenerative diseases or 
phenotypes.
4 Conclusions
We have presented a two dimensional imaging genetic enrichment analysis (IGEA) 
framework to explore the high level imaging genetic associations by integrating whole brain 
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genomic, transcriptomic and neuroanatomic data. Traditional pathway enrichment analysis 
focused on investigating genetic findings of a single phenotype one at a time, and 
relationships among imaging QTs could be ignored. Such approach could be inadequate to 
provide insights into the mechanisms of complex diseases that involve multiple genes and 
multiple QTs. In this paper, we have proposed a novel enrichment analysis paradigm IGEA 
to detect high level associations between gene sets and brain circuits. By jointly considering 
the complex relationships between interlinked genetic markers and correlated brain imaging 
phenotypes, IGEA provides additional power for extracting biological insights on 
neurogenomic associations at a systems biology level.
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Fig. 1. 
Overview of the proposed Imaging Genetic Enrichment Analysis (IGEA) framework. (A) 
Perform SNP-level GWAS of brain wide imaging measures. (B) Map SNP-level GWAS 
findings to gene-level. (C) Construct gene-ROI expression matrix from AHBA data. (D) 
Construct GS-BC modules by performing 2D hierarchical clustering, and filter out non-
significant 2D clusters. (E) Perform IGEA by mapping gene-level GWAS findings to 
identified GS-BC modules. (F) For each enriched GS-BC module, examine the GS using 
GO terms, KEGG pathways, and OMIM disease databases, and map the BC to the brain.
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Fig. 2. 
Seven unique brain circuits (BCs) identified from IGEA. ROIs belonging to each BC are 
colored in red.
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Fig. 3. 
Brain maps of four brain circuits (BCs) identified from IGEA.
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Table 2
Five unique gene sets (GSs) identified from IGEA.
GS ID Gene symbols
GS01 AASDHPPT, APOC1, APOC4, ARHGAP1, ARMC2, BCR, C16orf74, CHST11, COL25A1, DCLK3, DNAH6, DNAI1, DOCK4, 
DRD1, ELMOD1, ERLIN1, EXD2, EYA1, FAM107A, FAM118B, FZD2, GNAL, GPR6, GPR88, GSTM3, HTR4, HYDIN, IL17D, 
ITPK1, KLF5, MFN2, MIPEP, MLLT3, MMD2, MTHFD1, MYB, NCKAP1, NSUN3, PALM, PDE1B, PDYN, PFDN6, PHF21B, 
PPP1R1A, RAP1GAP, RGS14, RGS20, RNF44, SLC17A8, SLC2A4, STYXL1, TRIM69, UBQLN4, UBR7, VAX1, WNT8A, 
ZC3HAV1L, ZMAT2, ZNF883
GS02 ACSS1, CPLX1, CSMD2, DDX4, ITGB3, LRIG1, METTL7A, NDRG2, NPAS4, PDIA6, PLA2G5, POTED, PPARGC1A, PSD2, 
PXDNL, TFCP2L1, USH2A, VEGFA
GS03 ADPRHL2, ADRM1, AKR1A1, ANAPC2, AP4M1, AP5Z1, APBB1, APBB3, ARFGAP3, ARMC6, ASL, ATP5B, AUP1, 
AURKAIP1, B4GALT3, C17orf59, CAPN1, CCS, CCT3, CDIPT, COG4, CPNE1, CSNK2B, CSTF1, DAPK3, DDX21, DECR2, 
DEPDC5, DHPS, DHX16, DHX38, DNAJC30, EIF2B4, EIF2B5, ELOF1, ERAL1, FAM50B, FAM96B, FLII, GALK1, GGNBP2, 
GPAA1, GPATCH3, GPI, GPR137, HEXIM2, HN1, HOOK2, HPS6, IFFO1, KAT5, KHK, KLHL22, LDLR, LRSAM1, LZTR1, 
MAF1, MAGEF1, MFSD10, MMS19, MRPL38, MRPL54, NARFL, NCAPH2, NCLN, NISCH, NRBP1, NTHL1, PHB2, PI4KB, 
PIH1D1, POLD2, POLG, PPOX, PRDX2, PRMT1, PRPF31, PTBP2, PTOV1, RABGGTA, RALY, RPS19BP1, RRN3, SH2B1, 
SLC25A42, SLC41A3, SMPD1, SNRPA, SSNA1, STK19, STUB1, SULT1A1, TCEA2, TCEB3, TMED3, TMEM106C, 
TMEM161A, TOMM40, TRMU, TRPC4AP, TTC27, TUSC1, TXN2, TXNL4B, UBR4, YTHDF2, ZFAND2B
GS04 AIPL1, AP1M2, ARRDC5, CD1C, CST1, DEFB113, DEFB126, EPGN, FBP2, FGF19, FNDC7, FRG2, GPRC5D, IL22, INMT, 
KCNK18, KIF18A, KLRG2, KRT79, MBD3L2, MMP7, MS4A1, MS4A3, MSMB, NEIL3, OR13C3, OR1M1, OR4F15, OR51I2, 
OR5AN1, OR5AR1, OR5M1, OR7G3, PDZK1IP1, PRAMEF8, PTCHD3, RLN1, SIRPD, TBX20, TEDDM1, TGM3, TIAF1, 
TIMD4, TM4SF19, TM4SF20, TMC1, TPD52L3, WFDC13, XDH, ZFP42
GS05 ALDH9A1, ANKFN1, APOE, ATP6V0A4, BIN1, C11orf65, C15orf52, C1orf64, CD81, CDH1, CNN3, ECSCR, EDNRB, ENG, 
FAM84B, GGT5, GIMAP5, GPR137B, GREM1, GSTM2, GTF2F2, HRASLS2, ID1, LMO2, MAPKAPK3, MARCH10, PARP4, 
PAWR, PGR, PHF10, PLSCR4, PMAIP1, POLI, PRDX1, RAB13, RGS22, SDS, SLC2A1, SLC40A1, SMAD9, STX18, SULT1C4, 
SVOPL, TIE1, TM4SF18, TMEM204, TRIP6, TST, WASF2, WFDC3, WRB, WWC2
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